EFFICACY OF INCA033989 IN CHRONIC AND ADVANCED FORMS OF CALRDEL52 AND CALRINS5 MYELOPROLIFERATIVE NEOPLASMS (MPN) MODELS

EHA Library, Isabelle Plo, 419089

TAGRAXOFUSP EXHIBITS ANTITUMORAL ACTIVITY IN PRECLINICAL MODELS OF MYELOFIBROSIS AND ENHANCES ANTILEUKEMIC ACTIVITY OF JAK INHIBITORS

EHA Library, Vittoria Nicolis di Robilant, 419092

ADVANCING EARLY DETECTION AND IMPROVED TARGETED THERAPY IN MYELOPROLIFERATIVE NEOPLASMS: INSIGHTS FROM MULTIMODAL IMAGING AND NANOPARTICLE-MEDIATED DRUG DELIVERY

EHA Library, Julian Baumeister, 419093

SINGLE CELL MULTIOMICS IDENTIFIES ABERRANT COMMUNICATION BETWEEN DENDRITIC CELLS AND LEUKAEMIA STEM CELLS AS A THERAPEUTICALLY TARGETABLE AXIS IN JUVENILE MYELOMONOCYTIC LEUKAEMIA

EHA Library, Eleni Louka, 419094

TARGETED T CELLS AGAINST HEMATOPOIETIC CELLS EXPRESSING ONCOGENIC CALRETICULIN MUTANTS

EHA Library, Robert Kralovics, 419095

REAL WORLD PRACTICE REVEALS SERUM TNFΑ AS THE EARLY PROGNOSTIC PREDICTOR FOR MYELOFIBROSIS WITH RUXOLITINIB TREATMENT

EHA Library, Xinjie Chen, 419099

RKER-050, A MODIFIED ACTIVIN RECEPTOR TYPE IIA LIGAND TRAP, RESCUED ANEMIA AND INCREASED MUSCLE MASS AND STRENGTH IN A MOUSE MODEL OF MYELOFIBROSIS

EHA Library, Blake Moses, 419100

COMPLEX ALTERNATIVE SPLICING AND RELATED NEOANTIGEN PATTERNS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jing Sun, 419102

IMMUNOPHENOTYPIC ANALYSIS OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS RECEIVING THERAPY WITH THE BET INHIBITOR PELABRESIB

EHA Library, Rosa Andres Ejarque, 419103

T-CELL PHENOTYPING SUPPORTS THE USE OF T-CELL ENGAGING ANTIBODIES FOR TREATMENT OF CALRETICULIN MUTATED MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Anna Kuchnio, 419104

CDK8/19 INHIBITION: A PROMISING THERAPEUTIC STRATEGY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Zachary Zaroogian, 419105

FEDRATINIB INHIBITS IMMUNE EVASION AND RESTORES B CELL MATURATION: BIOMARKER ANALYSIS FROM THE FREEDOM2 STUDY

EHA Library, Claire Harrison, 419107

EFFECT OF NOVEL AGENTS ON THE MECHANISM OF FIBROCYTE-MEDIATED INDUCTION OF MYELOFIBROSIS

EHA Library, Takaaki Maekawa, 419108

INFLAMMATION NOT HAEMATOPOIESIS CAUSES SPLENOMEGALY IN A MOUSE MODEL OF POLYCYTHAEMIA VERA.

EHA Library, Cavan Bennett, 419109

MIR-93 ATTENUATES CALR MUTANT-DRIVEN ONCOGENIC ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Chih-Cheng Chen, 419111

HUMANIZED IMMUNOCOMPETENT MOUSE MODEL FOR THE PRECLINICAL THERAPEUTIC EVALUATION OF T CELL ENGAGING BISPECIFIC ANTIBODIES TARGETING CALRETICULIN MUTANT MPN

EHA Library, Shengen Xiong, 419112

DUPLICATION OF CHROMOSOME 9P INDUCES T CELL EXHAUSTION AND INCREASED CLONOGENICITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN JAK2-MUTANT MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ruggiero Norfo, 419113

MUTATIONAL LANDSCAPE OF PATIENTS ENROLLED IN THE LOW-PV TRIAL WITH ROPEGINTERFERON ALFA-2B

EHA Library, Paola Guglielmelli, 419114

UNVEILING THE EFFECTIVENESS AND PREDICTIVE FACTORS OF JAKTINIB TREATMENT IN MYELOFIBROSIS PATIENTS WITH ANEMIA

EHA Library, Huafeng Wang, 419118

IMPACT OF TP53 MUTATION ALLELIC BURDEN ON OUTCOME OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: A STUDY FROM COMMAND CONSORTIUM.

EHA Library, Talha Badar, 419120

EFFICACY OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS WHO HAVE OVERLAPPING THROMBOCYTOPENIA AND ANEMIA

EHA Library, Pankit Vachhani, 419124

LONG TERM FOLLOW-UP RESULTS OF PHASE II CLINICAL TRIAL EVALUATING RUXOLITINIB (RUX) AND AZACITIDINE (AZA) COMBINATION THERAPY IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

EHA Library, Sankalp Arora, 419126

A PHASE 2 STUDY OF PEMIGATINIB (FIGHT-203; INCB054828) IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE REARRANGEMENT

EHA Library, Alessandro Vannucchi, 419129

RUXOLITINIB STARTING DOSE REDUCTION AFFECT OVERALL SURVIVAL IN MYELOFIBROSIS: AIFA MONITORING REGISTRIES ANALYSIS

EHA Library, Massimo Breccia, 419130

A REAL-WORLD EVALUATION OF RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL

EHA Library, Michael Grunwald, 419134

THE TRIPLE A MODEL-AAA (AGE, ABSOLUTE NEUTROPHIL COUNT, ABSOLUTE LYMPHOCYTE COUNT) PREDICTS SURVIVAL AND THROMBOSIS IN POLYCYTHEMIA VERA

EHA Library, Ivan Krecak, 419135

RUXOLITINIB TREATMENT IN PATIENTS WITH POLYCYTHEMIA VERA REDUCES JAK2 ALLELE BURDEN AND IMPROVES HEMATOCRIT CONTROL AND SYMPTOM BURDEN

EHA Library, Claire Harrison, 419136

NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN POLYCYTHEMIA VERA (PV): CORRELATION WITH ROPEG-INTERFERON RESPONSE IN LOW PV TRIAL

EHA Library, Tiziano Barbui, 419137

FEDRATINIB IN PATIENTS WITH MYELOFIBROSIS EXPOSED TO RUXOLITINIB: AN INDIRECT TREATMENT COMPARISON WITH MOMELOTINIB AND PACRITINIB

EHA Library, Francesca Palandri, 419138

HIGH RATE OF DISEASE PROGRESSION IN PATIENTS WITH LOW-RISK MYELOFIBROSIS (MF) ENROLLED IN THE PROSPECTIVE MOST STUDY

EHA Library, Michael Grunwald, 419140

COMPREHENSIVE EVALUATION OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS: FINAL ANALYSIS RESULTS FROM A RANDOMIZED PHASE 3 STUDY

EHA Library, Huafeng Wang, 419141

HIGH RESOLUTION CHEST COMPUTED TOMOGRAPHY RESPONSES FOR A COHORT OF ADULT WITH PULMONARY LANGERHANS CELL HISTIOCYTOSIS

EHA Library, Long Chang, 419143

A NEW MACHINE LEARINING CLINICAL SCORE FOR THROMBOSIS RISK IN POLYCYTHEMIA VERA: THROMBOVERA CS

EHA Library, Isidora Arsenovic, 419144

‘REAL WORLD ANALYSIS APPLYING INTERNATIONAL PROGNOSTIC SCORE (IPSM) IN NON-ADVANCED SYSTEMIC MASTOCYTOSIS PATIENTS IN UK SINGLE CENTRE OF EXCELLENCE’

EHA Library, Priya Sriskandarajah, 419145

RECOGNITION OF SYMPTOM BURDEN IN MPN: DISCREPANCIES BETWEEN  PATIENT- AND PHYSICIAN-REPORTED ASSESSMENT – AN INTRA-INDIVIDUAL ANALYSIS BY THE GERMAN MPN STUDY GROUP (GSG-MPN)

EHA Library, Susanne Isfort, 419148

PROGNOSTIC IMPACT OF LEUKOCYTOSIS, MONOCYTOSIS AND EOSINOPHILIA IN ADVANCED SYSTEMIC MASTOCYTOSIS: A REGISTRY-BASED ANALYSIS OF THE GREM

EHA Library, Johannes Lübke, 419149

IMPACT OF GENETIC FACTORS IN THE OVERALL SURVIVAL OF PATIENTS WITH CALR-MUTATED MYELOFIBROSIS

EHA Library, Ruth Stuckey, 419153

SELINEXOR PLUS RUXOLITINIB IMPACT ON SYMPTOM BURDEN IN PATIENTS WITH MYELOFIBROSIS AND POTENTIAL MECHANISM OF ACTION VIA INHIBITION OF NF-ΚB AND ACTIVATION OF P53 PATHWAYS

EHA Library, Srinivas Tantravahi, 419156

CLINICAL PATTERNS AND THERAPEUTIC CONSIDERATIONS IN MALIGNANT HISTIOCYTOSES: A NATIONWIDE RETROSPECTIVE ANALYSIS

EHA Library, Camille Bigenwald, 419158

IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH SECONDARY MYELOFIBROSIS

EHA Library, Nico Gagelmann, 419161

GERMLINE INACTIVATING VARIANTS IN SH2B3 DEFINE A NOVEL DISORDER CHARACTERIZED BY A TRANSIENT NEONATAL/INFANCY MYELOPROLIFERATIVE DISORDER AND SUBSEQUENT DEVELOPMENT OF THROMBOCYTOSIS IN CHILDHOOD

EHA Library, Davide Leardini, 419162

TREATMENT OF ADVANCED STAGE, HIGH RISK SCORE HODGKIN'S DISEASE PATIENTS WITH CONVENTIONAL CHEMOTHERAPY PLUS BRENTUXIMAB VEDOTIN AND NIVOLUMAB: A PHASE II TRIAL RESULTS

EHA Library, Maher Salamoon, 419166

BRENTUXIMAB VEDOTIN (BV)+AVD IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTRIC STUDY

EHA Library, Giovanni Manfredi Assanto, 419167

PEMBROLIZUMAB PLUS THE ANTI–LAG-3 ANTIBODY FAVEZELIMAB FOR HEAVILY PRETREATED ANTI–PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): AN UPDATED ANALYSIS OF A PHASE 1/2 STUDY

EHA Library, Gareth Gregory, 419170

LONG-TERM CAUSE-SPECIFIC MORTALITY IN A COHORT OF 1,435 HODGKIN LYMPHOMAS TREATED AT THE NATIONAL ADULT PUBLIC CANCER PROGRAM IN CHILE OVER A 30-YEAR PERIOD

EHA Library, Massimo Federico, 419171

EVALUATION OF GONADAL FUNCTION IN YOUNG MEN AND WOMEN DIAGNOSED WITH HODGKIN LYMPHOMA

EHA Library, ANGELIKI GEORGOPOULOU, 419172

PEMBROLIZUMAB PLUS THE ANTI–LAG-3 ANTIBODY FAVEZELIMAB FOR ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA: AN UPDATED ANALYSIS OF A PHASE 1/2 STUDY

EHA Library, Peter Borchmann, 419174

RADIOTHERAPY-FREE TREATMENT IN GOOD PROGNOSIS EARLY-STAGE HODGKIN LYMPHOMA (RAFTING TRIAL-NCT ID.04866654). RESULTS OF PATIENT STRATIFICATION.

EHA Library, Jan Maciej Zaucha, 419176

INNOVATIVE EVA REGIMEN (ETOPOSIDE, VINBLASTINE, DOXORUBICIN) IN HODGKIN'S LYMPHOMA TREATMENT FOR PREGNANT WOMEN.

EHA Library, Joanna Romejko-Jarosińska, 419177

DATA REQUIREMENTS FOR DEVELOPMENT OF PREDICTION MODELS FOR SURVIVAL AMONG HODGKIN LYMPHOMA PATIENTS: HOW MANY PATIENTS ARE NEEDED?

EHA Library, Rasmus Rask Kragh Jørgensen, 419178

BASELINE PET-CT RADIOMICS PREDICT 5-YEAR PROGRESSION FREE SURVIVAL IN ADVANCED STAGE HODGKIN LYMPHOMA

EHA Library, Fer de Wit, 419179

EARLY DETECTION OF CLASSIC HODGKIN LYMPHOMA RELAPSE USING ROUTINE SERUM TARC MEASUREMENTS DURING FOLLOW-UP

EHA Library, Sophie Teesink, 419181

TREATMENT EFFECTS OF BRECADD ON HEALTH-RELATED QUALITY OF LIFE: AN ANALYSIS OF PATIENT REPORTED OUTCOMES IN THE RANDOMIZED INTERNATIONAL PHASE III GERMAN HODGKIN STUDY GROUP HD21 TRIAL

EHA Library, Justin Ferdinandus, 419187

SAFETY AND EFFICACY OF SYK INHIBITOR SOVLEPLENIB IN HEAVILY PRE-TREATED HODGKIN LYMPHOMA PATIENTS

EHA Library, Paolo Strati, 419189

SAFETY AND EFFICACY RESULTS FROM AN OPEN-LABEL PHASE 1/2 TRIAL OF SABESTOMIG (AZD7789) IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PREVIOUSLY TREATED WITH ANTI-PD-(L)1 THERAPIES

EHA Library, Gaetano Corazzelli, 419190

A NATIONWIDE STUDY OF NEWLY DIAGNOSED NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA OVER TWO DECADES

EHA Library, Katrin Bamdeg-Hvolbek, 419191

COMBINATION OF BRENTUXIMAB VEDOTIN AND PEMBROLIZUMAB BEFORE INTENSIFICATION WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA.

EHA Library, Hanne Massa, 419192

OUTCOME OF PATIENTS WITH LIMITED-STAGE HODGKIN LYMPHOMA (HL) ENROLLED IN THE EORTC/LYSA/FIL H10 AND PROGRESSED/RELAPSED AFTER INITIAL THERAPY

EHA Library, Manuel Gotti, 419194

TIMING MATTERS: IMPACT OF EARLY HISTOLOGICAL TRANSFORMATION ON SURVIVAL IN FOLLICULAR LYMPHOMA (FL) PATIENTS: A MULTICENTRE ANALYSIS

EHA Library, Andrea Franch, 419195

TUMOR ASSOCIATED MACROPHAGES’ CYTOKINES; CD163, CCL4 AND CCL2, AS POSSIBLE NEW BIOMARKERS IN WALDENSTROM’S MACROGLOBULINEMIA.

EHA Library, Alexandros Gkiokas, 419196

WAVE STUDY, A RETROSPECTIVE OF FILO TRIAL : PATIENTS WITH RELAPSE WALDENSTRÖM'S MACROGLOBULINEMIA TREATED BY VENETOCLAX IN REAL LIFE

EHA Library, Mathilde Vonfeld, 419200

PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA TREATED WITH EPCORITAMAB

EHA Library, Wojciech Jurczak, 419201

BENEFIT OF RITUXIMAB MAINTENANCE AFTER FIRST-LINE BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Yucai Wang, 419204

PRELIMINARY EFFICACY AND SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB-16673 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) INDOLENT NHL: RESULTS FROM THE PHASE 1 BGB-16673-101 STUDY

EHA Library, Chan Cheah, 419206

ZR STUDY：A PROSPECTIVE PHASE II STUDY OF ZANUBRUTINIB-RITUXIMAB INDUCTION WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED MANTLE CELL LYMPHOMA

EHA Library, Chang-Ju Qu, 419207

MATCHING-ADJUSTED INDIRECT COMPARISONS OF EPCORITAMAB VS MOSUNETUZUMAB OR ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES

EHA Library, Alexey Danilov, 419208

REAL-WORLD EVALUATION OF TREATMENT PATTERN, TIME TO NEXT TREATMENT, HEALTHCARE RESOURCE UTILIZATION, AND COST OF CARE IN FOLLICULAR LYMPHOMA

EHA Library, Sameh Gaballa, 419211

TP53 AND CDKN2A DISRUPTIONS ARE INDEPENDENT PROGNOSTIC DRIVERS IN MANTLE CELL LYMPHOMA: LONG TERM OUTCOME OF THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 TRIAL

EHA Library, Riccardo Moia, 419212

CLINICAL CHARACTERISTICS AND OUTCOMES OF MCL PATIENTS AGED 80 YEARS AND OLDER

EHA Library, Simon Pahnke, 419216

VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL OR ARI-0001) IN RELAPSED / REFRACTORY ADULT FOLLICULAR LYMPHOMA

EHA Library, Nuria Martinez-Cibrian, 419217

PATIENT CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL) IN THE UNITED STATES (US), CANADA, AND EUROPE: A PANEL-BASED CHART REVIEW STUDY

EHA Library, Craig Portell, 419221

PRELIMINARY SAFETY AND EFFICACY OF BOVEN (ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX) FOR FRONTLINE THERAPY FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Anita Kumar, 419225

ORELABRUTINIB-LENALIDOMIDE-RITUXIMAB IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (MCL): UPDATED RESULTS OF THE MULTICENTER, PHASE II POLARIS STUDY

EHA Library, Huilai Zhang, 419228

INCIDENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA: A SINGLE CENTRE REAL-WORLD EXPERIENCE

EHA Library, Nicole Japzon, 419231

CLINICAL EFFICACY OF RUXOLITINIB IN T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA VIA A NON-TUMOR CELL AUTONOMOUS MECHANISM

EHA Library, Amira Marouf, 419234

FRONTLINE TREATMENT WITH ZANUBRUTINIB PLUS RITUXIMAB (ZR) FOLLOWED BY SHORT COURSE R-DHAOX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) – RESULTS OF PHASE II CHESS TRIAL

EHA Library, Qingqing Cai, 419235

EZH2 ABERRATIONS IN ADVANCED FOLLICULAR LYMPHOMA: FIRST TRANSLATIONAL RESULTS OF FOLL-EZ, AN ANCILLARY STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL

EHA Library, Simone Ferrero, 419236

OUTCOMES IN PATIENTS WITH LARGE B-CELL LYMPHOMA TREATED WITH TAFASITAMAB PLUS LENALIDOMIDE POST-CD19-TARGETING CAR-T THERAPY: A LYSA STUDY FROM THE DESCAR-T REGISTRY

EHA Library, Vincent Camus, 419240

SECONDARY PRIMARY MALIGNANCIES AFTER CD19-DIRECTED CAR-T CELL THERAPY IN LYMPHOMAS: A REPORT FROM THE ITALIAN CART-SIE STUDY

EHA Library, Angelica Barone, 419243

BRIGATINIB MONOTHERAPY IN CHILDREN WITH R/R ALK+ ALCL: PRELIMINARY RESULTS FROM THE BRIGAPED (ITCC-098) PHASE 1 DOSE-ESCALATION STUDY

EHA Library, Charlotte Rigaud, 419245

A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY WITH A PD-1 KNOCKOUT (CB-010) FOR RELAPSED/REFRACTORY B CELL NON-HODGKIN LYMPHOMA (R/R B-NHL): UPDATED PHASE 1 RESULTS FROM THE ANTLER TRIAL

EHA Library, Boyu Hu, 419247

ODRONEXTAMAB DEMONSTRATES DURABLE COMPLETE RESPONSES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PROGRESSING AFTER CAR-T THERAPY: OUTCOMES FROM THE ELM-1 STUDY

EHA Library, Jean-Marie Michot, 419249

PLASMA CELL-FREE DNA AS AN ALTERNATIVE TO TISSUE DNA FOR DETECTING GENETIC ALTERATIONS OF IVLBCL

EHA Library, Chao Chen, 419250

SUPERIOR EFFECTS OF CD19/20 DUAL-TARGETING CAR-T IN PATIENTS WITH RELAPSED/REFRACTIVE B-CELL LYMPHOMA: A MULTICENTER PRELIMINARY INTERIM REPORT

EHA Library, Jiaqi Guo, 419251

REAL-WORLD ANALYSIS OF GLOFITAMAB FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN GERMANY, AUSTRIA AND SWITZERLAND

EHA Library, Rebecca Wurm-Kuczera, 419253

ORIENT STUDY: ORELABRUTINIB ADDITION TO R-CHOP-LIKE REGIMEN ADAPTED TO RESPONSE IN TREATMENT-NAÏVE NON-GCB DLBCL

EHA Library, Chang-Ju Qu, 419254

PHASE 2 STUDY OF ANTI-PD-L1 ANTIBODY ATEZOLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA: NCCH1903/ATTACK STUDY

EHA Library, Shinichi Makita, 419257

ANALYSIS OF CCND3 MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Jin-Hua Liang, 419261

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) - FINNISH REAL-LIFE DATA WITH LONG-TERM FOLLOW-UP ON 215 SOLID ORGAN RECIPIENTS

EHA Library, Terhi Friman, 419263

THE PROGNOSTIC SIGNIFICANCE OF MYC/BCL2 DOUBLE EXPRESSION IN DIFFUSE LARGE B CELL LYMPHOMA IN THE GENETIC CLASSIFICATION ERA

EHA Library, Jin-Hua Liang, 419264

BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS– UPDATED ANALYSIS OF REAL-WORLD DATA

EHA Library, Magdalena Klanova, 419265

CD19/BCMA DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA: AN UPDATE

EHA Library, Xinfeng Chen, 419268

REAL-WORLD EXPERIENCE OF POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB AND BENDAMUSTINE IN RELAPSED AND REFRACTORY LARGE B-CELL LYMPHOMAS.

EHA Library, Michał Danecki, 419269

A VISUAL NOMOGRAM SURVIVAL PREDICTION MODEL IN ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)-RELATED DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, chongling Hu, 419271

ZANUBRUTINIB, LENALIDOMIDE, RITUXIMAB, TEMOZOLOMIDE AND METHOTREXATE (RLZT±MTX) AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PCNSL: A PROSPECTIVE, OPEN-LABEL, MULTICENTER CLINICAL TRIAL

EHA Library, Jia Song, 419272

SIGNIFICANT OUTCOME IMPROVEMENT OF THE ENTIRE R/R DLBCL POPULATION RECEIVING THIRD LINE THERAPY IN THE CAR T-CELL ERA

EHA Library, Marek Trneny, 419273

BASELINE PET TOTAL METABOLIC TUMOR VOLUME HAS A PROGNOSTIC ROLE IN PTCLS – DATA FROM INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0

EHA Library, Tetiana Skrypets, 419275

CAR-T CELL THERAPY SHOWS SIMILAR EFFICACY AND TOXICITY IN PATIENTS WITH DLBCL AGED 70 AND OLDER COMPARED TO YOUNGER PATIENTS: A MULTICENTER COHORT STUDY

EHA Library, Philipp Berning, 419279

ORELABRUTINIB IN COMBINATION WITH PD-1 INHIBITOR IN REFRACTORY OR RELAPSED PRIMARY CNS LYMPHOMA

EHA Library, Yan Zhang, 419281

NIVOLUMAB CONSOLIDATION AFTER DA-EPOCH-R INDUCTION INDUCES HIGH RATES OF DISEASE-FREE AND OVERALL SURVIVAL IN PATIENTS WITH DOUBLE AND TRIPLE HIT HIGH-GRADE B-CELL LYMPHOMA

EHA Library, Martine Chamuleau, 419285